Blood Diseases
Articles tagged with Blood Diseases
CODA supports international collaboration between Stellenbosch University and Massachusetts Institute of Technology to advance microvascular research in complex chronic disorders
Physical exercise may improve stem cell donation
A pilot study suggests that physical exercise can support stem cell donation by releasing specific types of blood stem cells into the bloodstream. The exercise stimulus increases stem cell numbers only moderately, but may offer a more targeted approach than medication.
Study finds regional differences in sickle cell disease in New York state
A new study reveals significant variation in sickle cell disease hospitalizations and costs across New York State, with regional differences in access to specialized care and treatment impacting outcomes. Long Island and New York City show high costs and complex cases, while Central New York has the longest average length of stay.
Novel, fast-acting therapy benefits patients with platelet disorder in phase 2 trial
A phase 2 clinical trial shows that mezagitamab can effectively increase platelet counts in patients with immune thrombocytopenia, improving quality of life. The investigational medication has a rapid effect, normalizing platelet counts in 48 hours.
CAR-T therapy drives remission in patient with three autoimmune diseases
Scientists used CAR-T cell therapy to treat a patient with severe autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid antibody syndrome. The treatment achieved lasting remission without additional treatment for over a year.
ASH publishes clinical practice guidelines on diagnosis and management of severe and very severe acquired aplastic anemia
The American Society of Hematology has published clinical practice guidelines for diagnosing and managing severe acquired aplastic anemia, a rare and life-threatening bone marrow failure disorder. The guidelines highlight the importance of shared decision-making between patients and providers, as well as the need for additional researc...
Gene editing therapy shows success against severe sickle cell disease
A gene-edited treatment has shown remarkable success against severe sickle cell disease, with 27 out of 28 patients achieving a functional cure and no painful crises. The therapy uses CRISPR/Cas12a technology to modify stem cells and increase levels of fetal hemoglobin.
Global, China–US burden of hematological malignancies: New data reveals trends and risks
Hematological malignancies are a major global health challenge, with the US and China experiencing distinct epidemiological patterns. The study reveals that NHL is the most common type globally and in the US, while leukemia leads in incidence in China.
Phase 3 study: New therapy keeps gastrointestinal cancer care on course when low platelets are an obstacle
A phase 3 clinical trial found romiplostim significantly reduced chemotherapy dose delays and improved platelet counts in patients with gastrointestinal cancers who developed persistent low platelet counts during treatment. The therapy enables patients to maintain chemotherapy intensity, potentially preserving the integrity of cancer c...
Romiplostim prevents serious side effect of chemotherapy in phase 3 trial
A phase 3 clinical trial by Mass General Brigham reveals romiplostim's ability to prevent chemotherapy-induced thrombocytopenia, allowing full-dose chemotherapy delivery. The medication boosts bone marrow's resistance to chemotherapy, reducing the risk of life-threatening bleeding and improving cancer treatment outcomes.
Researchers develop a biomimetic platform to enhance CAR T cell therapy against leukemia
Researchers developed a biomimetic platform to enhance CAR T cell therapy against leukemia by creating a molecular bridge that reinforces the interface between CAR T cells and leukemia cells. This platform, called FACE, uses ferritin to bind to CD71 on leukemia cells, improving cell recognition and elimination.
Hidden genetic mismatch, which triples the risk of a life-threatening immune attack after cord blood transplantation
A large registry study identifies a specific genetic mismatch linked to severe acute graft-versus-host disease (aGVHD) after cord blood transplantation, tripling the risk of life-threatening complications. Researchers found that a particular HLA combination in donors and recipients increased aGVHD risk by threefold.
New strategies boost effectiveness of CAR-NK therapy against cancer
Researchers at the Center for Cell-Based Therapy developed a new approach to enhance CAR-NK cell cytotoxicity, combining optimized co-stimulation with reversible pharmacological control. The study showed increased tumor control in animal models, paving the way for improved cancer treatment.
Scientists map brain's blood pressure control center
A group of nerve cells in the brainstem has been identified as a stabilizing system for blood pressure, preventing fluctuations between daily activities. The study suggests that loss or dysfunction of these cells can lead to unstable blood pressure and is associated with conditions such as multiple system atrophy.
Renowned developmental biologist wins March of Dimes Prize
Dr. Zon's pioneering research has illuminated how blood develops in embryos, leading to a deeper understanding of rare blood diseases, including pregnancy complications. His discoveries have also led to breakthrough treatments for genetic blood disorders affecting babies and children.
The ACHILLES project will train a new generation of researchers in experimental haemato-oncology to tackle leukemia and lymphoma
The ACHILLES project trains researchers in experimental haematological oncology, developing advanced models, analysis tools, and therapeutic targets for leukaemia and lymphoma. The project aims to bridge basic and preclinical research with clinical practice, improving survival rates and accessibility to innovative treatments.
Scientists reveal splicing-based mechanism driving therapy resistance in pediatric acute myeloid leukemia
Researchers identify sequence-dependent RNA splicing abnormalities in 36% of pediatric AML cases, linked to lower complete remission rates and poorer survival. Functional dysregulation of U2AF2 protein drives aberrant splicing, which can be targeted by pharmacological modulation of PRMT enzymes.
Global study to evaluate whether dengue outbreaks can be anticipated earlier
A global study evaluates whether a new early-warning platform can support earlier interventions against dengue outbreaks. The E-Dengue platform, tailored for district-level decision-making, has been integrated into Vietnam's routine dengue surveillance and will be tested in a large cluster randomized controlled trial.
Sylvester Cancer Tip Sheet for December 2025
A virtual diet and exercise program has been shown to reduce treatment side effects and increase treatment retention, according to a Sylvester study presented at ASH 2025. Lifestyle interventions can also help patients with blood cancers such as MDS and large B-cell lymphoma receive more effective and less toxic treatments.
Tropical disease oroya fever: Elucidation of disease mechanism opens possibility for novel therapy
A team of researchers has identified two proteins critical to the destruction of red blood cells by the Oroya fever pathogen. This discovery paves the way for a potential novel therapy against this deadly neglected tropical disease.
Large-scale study provides real-world data on rare side effect of cancer immunotherapy
A large-scale study identified risk factors and clinical features of ICI-ITP, a rare but serious complication of anti-cancer immunotherapy. The study found that patients with ICI-ITP tend to have lower platelet counts at the start of treatment, experience additional immune-related adverse events, and have a higher risk of death.
Improving treatment for an autoimmune bleeding condition
A Phase III clinical trial found that over half of patients who received ianalumab for primary ITP maintained safe platelet counts without serious bleeding episodes for at least one year. The study suggests a new treatment option with the potential to improve long-term quality of life for patients.
ASH 2025: Study connects Agent Orange exposure to earlier and more severe cases of myelodysplastic syndrome
A new national study reveals a strong link between Agent Orange exposure and the risk of developing myelodysplastic syndrome, with exposed veterans diagnosed at younger ages and experiencing more aggressive disease. The study found that those with MDS were nearly twice as likely to see their disease progress within two years after diag...
ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer
A new study presented at the 2025 American Society of Hematology meeting revealed that subtle disruptions in genome architecture can predispose individuals to lymphoma. The research found that damaged 3D genome architecture can silence key tumor suppressor genes, creating fertile ground for malignancy.
Fred Hutch at ASH: Expanding CAR-T access, AML treatment strategies, climate and cancer — and ASH lifetime achievement award
Fred Hutch experts will present CAR-T access expansion, new AML treatment strategies, and the impact of climate on cancer. Experts discuss optimizing maintenance therapy using MRD-directed approaches for high-risk AML patients and evaluating the safety & efficacy of combining PIVEK with FLAG-IDA for adults with untreated AML.
Penn Medicine at the 2025 ASH Annual Meeting
Researchers from Penn Medicine will present data on latest advances in blood cancer and classical hematology research at the 67th American Society of Hematology Annual Meeting. The presentation includes updates on preclinical, clinical, and population-based research, as well as a multicenter Phase II study and a randomized phase III tr...
Why metabolism matters in Fanconi anemia
A new study from Cincinnati Children's reveals how Fanconi anemia disrupts energy pathways and affects glucose metabolism, paving the way for targeted dietary interventions to improve health and reduce cancer risk. The research uses isotope tracing metabolomics to track nutrient metabolism in people with FA.
Drug developed for inherited bleeding disorder shows promising trial results
A new study found that engasertib reduced nosebleed frequency and duration in patients with hereditary hemorrhagic telangiectasia (HHT), a rare inherited bleeding disorder. The trial also showed improved symptoms and safety profile for the drug, paving the way for its potential use as a treatment option.
Much-needed new drug approved for deadliest blood cancer
Researchers at the University of Virginia Health System have developed a new treatment for acute myeloid leukemia, a deadly form of blood cancer. The FDA-approved medication works by disrupting cellular protein interactions that drive leukemia cell growth and survival, offering patients a potential cure.
Researchers build bone marrow model entirely from human cells
Scientists have created a complex tissue model of human bone marrow using only human cells, replicating the cellular complexity of the body's 'blood factory'. This breakthrough reduces the need for animal experiments in blood cancer research and potentially enables personalized therapies.
ASH 2025 posters preview from Sylvester Comprehensive Cancer Center
Researchers from the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center will present their work on various hematological conditions at ASH 2025. These posters highlight recent findings in fields such as von Willebrand disease, multiple myeloma, and acute myeloid leukemia.
Scientists use stem cells to move closer to large-scale manufacturing of platelets
Researchers at Kyoto University create a method to produce platelet-producing cells from stem cells, offering an unlimited supply of patient-derived platelets. Monitoring KAT7 levels can help ensure efficient and consistent platelet manufacturing.
Clinical characteristics and outcomes of portal vein thrombosis in patients with porto-sinusoidal vascular disease
A study of 169 patients with porto-sinusoidal vascular disease found that portal vein thrombosis was associated with higher rates of esophageal variceal bleeding, ascites, and antithrombin III deficiency. The study also reported a higher risk of mortality in patients with PVT compared to those without.
ASH 2025 tip sheet: Sylvester researchers contribute to more than 35 oral presentations at ASH Annual Meeting
Multiple Sylvester physicians presented their research on various hematological cancers, including lymphoma and myeloma. The studies showcased promising results for treatments such as CAR-T therapy and immunotherapy combinations.
Alliance Global study challenges age-based treatment decisions in leukemia
A recent study published in Leukemia found that age-based classifications in acute myeloid leukemia (AML) treatment may be outdated. The research analyzed data from 2,823 adult AML patients, revealing nuanced age-related trends in genetic mutations and survival outcomes.
New lab-grown human embryo model produces blood cells
Researchers at the University of Cambridge have developed a new lab-grown human embryo model that replicates early human development, including the production of blood stem cells. The 'hematoids' model mimics the natural developmental process, offering potential medical advances in screening drugs and studying blood disorders.
Researchers at the Josep Carreras Institute describe for the first time the delicate balance of longevity
A team of researchers led by Dr. Manel Esteller has published a study on the longest-lived person ever recorded, Maria Branyas, who reached 117 years. The analysis reveals a fascinating duality: simultaneous presence of signals of extreme aging and healthy longevity. Despite signs of aging, Branyas had genetic characteristics associate...
Study: Evaluating chatbot accuracy in the fast-changing blood cancer field
A new study assesses ChatGPT 3.5's performance on hematology-oncology tasks, revealing its strengths and limitations in providing accurate information for patients. The study highlights the importance of physician oversight when using AI-generated medical information.
Common inflammation drug may slow blood mutation, related CVD risk
A subanalysis of the LoDoCo2 trial found that low-dose colchicine slows the growth of clonal hematopoiesis, a common acquired gene mutation linked to cardiovascular disease and cancer. Colchicine was associated with significantly attenuated clonal growth in TET2-mutated CH.
New CRISPR technique could rewrite future of genetic disease treatment
Researchers have developed a new epigenetic editing method using CRISPR technology, which can switch genes back on by removing methyl groups attached to silenced or suppressed genes. This approach shows promise for treating people with Sickle Cell-related diseases, reducing the risk of unwanted changes and potential health problems.
New monoclonal antibody targets deadly sepsis
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
Blood cancer therapy: DKMS John Hansen Research Grant 2026 supports innovative research projects with almost €1 million
The DKMS John Hansen Research Grant is supporting innovative research projects in blood cancer therapy, aiming to improve treatment outcomes. The grant, worth almost €1 million, will support young scientists with a focus on transplant immunology and novel diagnostic and therapeutic strategies.
Centuries after discovery, red blood cells still hold surprises
Researchers at University of Pennsylvania discover red blood cells contribute to clot contraction, shrinking and stabilizing blood clots. The finding opens door to new strategies for studying and treating clotting disorders, such as excessive bleeding or dangerous clots like those seen in strokes.
Study: olutasidenib is highly effective in certain patients with myelodysplastic syndrome
Researchers found olutasidenib to be highly effective in patients with myelodysplastic syndrome (MDS) and IDH1 mutations. The study showed a response rate of 59% and improved blood count improvement, long duration of response, and overall survival rates. This breakthrough offers new treatment options for these patients.
‘Mismatched’ transplants now safe, effective for blood cancer patients, study finds
A new treatment approach using cyclophosphamide has been found to prevent most graft-versus-host disease in mismatched transplants. The study shows that 80% of patients are alive after a year, similar to outcomes seen in fully matched transplants.
Partial match parity: Increasing the donor pool for hematopoietic stem cell transplantation
A recent study found that blood cancer patients achieve good outcomes with a partial match drawn from the national public registry of donors when treated with cyclophosphamide. Survival rates at one year were comparable to those seen in other studies with fully matched donors.
Genetic link found between iron deficiency and Crohn’s disease
Researchers identified a gene mutation that disrupts iron absorption in patients with Crohn's disease, leading to persistent anemia. The study sheds light on how genetic risk factors for IBD can compound patient symptoms by interfering with nutrient absorption.
Study identifies proteins involved in the effectiveness of immunotherapy against blood cancer
The study identified key proteins and signaling pathways involved in CAR-T cell therapy's efficacy, including cytokines, kinases, receptors, proteases, and chemical messengers. The findings pave the way for new treatment advances and potential biomarkers.
New study reveals why common leukemia treatments fail in some patients
A new study published in Blood Cancer Discovery found that certain gene mutations and the maturity of leukemia cells affect how patients respond to venetoclax and hypomethylating agents. Researchers identified a subtype of acute myeloid leukemia with worse outcomes, particularly those without the NPM1 mutation.
New US$35M partnership to advance blood disorder therapies
A new partnership between Murdoch Children's Research Institute and Retro Biosciences will advance personalized therapies for children and adults with bone marrow failure, leukaemia, and other blood disorders. The $35M agreement aims to develop autologous therapies using the breakthrough blood stem cell discovery.
New US$35M partnership to advance blood disorder therapies
A new partnership between Murdoch Children's Research Institute and Retro Biosciences aims to develop personalized blood stem cell treatments for children and adults with blood disorders. The collaboration has the potential to prevent complications from mismatched donors by using a patient's own perfectly matched cells in transplants.
New study: high efficiency of severe thalassemia prevention with HTS based carrier screening
A recent study found that strict adherence to High-Throughput Sequencing (HTS) technology based carrier screening can achieve high efficiency in preventing severe thalassemia birth defects. The study identified 15.07% of women as carriers of thalassemia and confirmed 59 fetuses with severe thalassemia, all of which were in high-risk co...
A new CAR-T therapy from Sant Pau achieves positive results in a high proportion of patients with a refractory type of lymphoma
A new CAR-T therapy, HSP-CAR30, has achieved positive results in a high proportion of patients with refractory CD30+ lymphoma. The treatment promotes the expansion of memory T cells, leading to durable responses and improved clinical outcomes.
Long-term survival rates of some Acute Myeloid Leukaemia patients could double with sensitive bone marrow test
A highly sensitive bone marrow test has shown to double survival rates for patients with AML mutations in NPM1 and FLT3 genes, allowing for early detection of potential relapse. This trial indicates that regular molecular testing can improve long-term survival rates by restarting treatment earlier.
IU scientists develop new bone marrow imaging technique
A new imaging technique developed by IU scientists allows for the visualization of 25 cellular markers in intact bone marrow tissue without disruption. This advancement could support future drug development and therapies for conditions involving bone marrow.
Minimal TV viewing may be protective for heart diseases linked to Type 2 diabetes
A new study found that limiting TV viewing to one hour or less daily may help offset an increased risk of heart and blood vessel diseases for people with a genetic risk for Type 2 diabetes. This suggests that reducing TV watching could serve as a key behavioral target for preventing atherosclerotic cardiovascular diseases linked to Typ...
Injectable Therapy is 'magic' for those who can’t take HIV pills
A new study by researchers at UCSF has found that long-acting injectable treatments can be transformative for patients who struggle to take daily HIV pills, resulting in undetectable viral loads and improved health outcomes. The treatment approach could help stop the spread of HIV by keeping more patients from being infectious.
Gordon Keller receives the 2025 ISSCR Achievement Award for his seminal work in regenerative medicine
Dr. Gordon Keller's groundbreaking research on directed differentiation of human pluripotent stem cells has illuminated the path to transforming human health. His lab's world-first discovery and pioneering efforts have pushed the boundaries of what is possible, offering hope for regenerating heart, liver, and blood cells.
Cutting back on alcohol may be more effective than immediately abstaining for preventing misuse among college students
A Texas A&M University researcher found that reducing alcohol consumption aligns with a harm reduction approach, which may be a more feasible approach for high-risk college drinkers. The study surveyed 822 high-risk college students and analyzed their intention to reduce drinking using the Theory of Planned Behavior.